Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Velcade in Metastatic or Locally Recurrent Nasopharyngeal Carcinoma
NCT00367718Phase 2Withdrawn
- Sponsor
- Johns Hopkins University
- Modality
- Small Molecules, Modified Peptides
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of bortezomib in nasopharyngeal carcinoma (NPC), sponsored by Johns Hopkins University. Primary endpoint: Efficacy based on response of measurable disease. Status: withdrawn.
02
Drugs
bortezomib
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT00367718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00367718.